IBN Sina Pharma's profit grows 13% in H1
IBN Sina Pharmaceutical Industry has disclosed a substantial 13% growth in profit for the July-December period of the fiscal year 2023-24.
The drug producer unveiled the half-yearly financial statement of FY2023-24 at a meeting held on Sunday (28 January).
According to the price-sensitive statement, its consolidated earnings per share was Tk11.92, which was Tk10.53 a year ago.
Keep updated, follow The Business Standard's Google news channel
Its shares closed at Tk262.70 each on Sunday, which was 0.15% lower than the previous session at the Dhaka Stock Exchange.
